Literature DB >> 17613359

Current and future hepatitis C therapies.

Roberto J Firpi1, David R Nelson.   

Abstract

Treatment of chronic hepatitis C patients has evolved significantly in the past 15 years. With a better knowledge of viral kinetics and molecular virology of the hepatitis C virus, we have gone from a low chance of viral eradication to a chance as high as 50%. Despite this, current therapies are not ideal and are associated with side effects, complications, and poor patient tolerability. Therefore, an urgent need to look for better strategies to treat this disease is imperative. Thanks to the current knowledge and ongoing research, we know the way we treat hepatitis C today will change dramatically in the next 5-10 years. This review will focus on current therapies for hepatitis C and the most recent advances in the search for new therapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17613359     DOI: 10.1016/j.arcmed.2006.09.002

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  11 in total

1.  A model of patient choice with mid-therapy information.

Authors:  William C Grant; Teresa L Kauf
Journal:  Patient       Date:  2009-09-01       Impact factor: 3.883

2.  Restoration of type I interferon expression by heme and related tetrapyrroles through inhibition of NS3/4A protease.

Authors:  Zhaowen Zhu; M Meleah Mathahs; Warren N Schmidt
Journal:  J Infect Dis       Date:  2013-07-29       Impact factor: 5.226

3.  Biliverdin inhibits hepatitis C virus nonstructural 3/4A protease activity: mechanism for the antiviral effects of heme oxygenase?

Authors:  Zhaowen Zhu; Anne T Wilson; Bruce A Luxon; Kyle E Brown; M Meleah Mathahs; Sarmistha Bandyopadhyay; Anton P McCaffrey; Warren N Schmidt
Journal:  Hepatology       Date:  2010-12       Impact factor: 17.425

4.  Risk factor profiles among intravenous drug using young adults: a latent class analysis (LCA) approach.

Authors:  Sigrid James; Edward S McField; Susanne B Montgomery
Journal:  Addict Behav       Date:  2012-09-23       Impact factor: 3.913

5.  Effects of a hepatitis C virus educational intervention or a motivational intervention on alcohol use, injection drug use, and sexual risk behaviors among injection drug users.

Authors:  William A Zule; Elizabeth C Costenbader; Curtis M Coomes; Wendee M Wechsberg
Journal:  Am J Public Health       Date:  2009-02-12       Impact factor: 9.308

6.  Heme oxygenase-1 suppresses hepatitis C virus replication and increases resistance of hepatocytes to oxidant injury.

Authors:  Zhaowen Zhu; Anne T Wilson; M Meleah Mathahs; Feng Wen; Kyle E Brown; Bruce A Luxon; Warren N Schmidt
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

7.  Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes.

Authors:  Abdo A Elfiky; Wael M Elshemey; Wissam A Gawad; Omar S Desoky
Journal:  Protein J       Date:  2013-01       Impact factor: 2.371

8.  Predictive impact of polymorphism of PNPLA3 on HCC development after interferon therapy in Japanese patients with chronic hepatitis C.

Authors:  Yuki Moritou; Fusao Ikeda; Yoshiaki Iwasaki; Nobuyuki Baba; Kouichi Takaguchi; Tomonori Senoh; Takuya Nagano; Yasuto Takeuchi; Tetsuya Yasunaka; Hideki Ohnishi; Yasuhiro Miyake; Akinobu Takaki; Kazuhiro Nouso; Kazuhide Yamamoto
Journal:  Springerplus       Date:  2013-06-01

9.  Heme and HO-1 Inhibition of HCV, HBV, and HIV.

Authors:  Warren N Schmidt; M Meleah Mathahs; Zhaowen Zhu
Journal:  Front Pharmacol       Date:  2012-10-04       Impact factor: 5.810

10.  Substituted imidazopyridines as potent inhibitors of HCV replication.

Authors:  Inge Vliegen; Jan Paeshuyse; Tine De Burghgraeve; Laura S Lehman; Matthew Paulson; I-Hung Shih; Eric Mabery; Nina Boddeker; Erik De Clercq; Hans Reiser; David Oare; William A Lee; Weidong Zhong; Steven Bondy; Gerhard Pürstinger; Johan Neyts
Journal:  J Hepatol       Date:  2009-02-26       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.